The company's focus is on identifying and targeting protein aggregates of tau, alpha-synuclein, and other proteins critical in the pathogenesis of neurodegenerative diseases like Alzheimer's and Parkinson's. APRINOIA operates in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston, providing clinical research and development services to establish a drug discovery and early-stage firm. Their goal is to create innovative products, including imaging-based diagnostic tools and therapies, to treat human neurological conditions.